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Abstract Tumor-induced osteomalacia is a rare acquired
metabolic bone disorder characterized by isolated renal
phosphate wasting due to abnormal tumor production of
ﬁbroblast growth factor 23. We report the case of a 59 year
old woman referred to our department with a long history of
progressive diffuse muscle weakness and pain, generalized
bone pains and multiple insufﬁciency fractures of heels,
ankles and hips due to a hypophosphatemic osteomalacia.
A ﬁbroblast growth factor 23-producing phosphaturic
mesenchymal tumor localized in the left quadriceps femoris
muscle was identiﬁed 7 years after onset of symptoms.
Excision of the tumor resulted in normalization of serum
phosphate and ﬁbroblast growth factor 23 levels and in
complete resolution of the clinical picture with dis-
appearance of all musculoskeletal symptoms. This case
illustrates the diagnostic difﬁculties in establishing a diag-
nosis tumor-induced osteomalacia and in identifying the
responsible tumor. Our case underscores the clinical need to
investigate all patients with persistent musculoskeletal
symptoms for hypophosphatemia. A systematic approach is
of pivotal importance because early recognition and
treatment of the metabolic abnormality can prevent dele-
terious effects of osteomalacia on the skeleton.
Keywords Tumor-induced osteomalacia (TIO) ● Fibroblast
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Introduction
Tumor-induced osteomalacia (TIO) is a rare acquired
metabolic bone disorder occurring as a result of isolated
renal phosphate wasting due to abnormal tumor production
of ﬁbroblast growth factor 23 (FGF23). Lack of awareness
of the clinical manifestations of the disorder often leads to
diagnostic delay, failure of diagnosis or misdiagnosis. Once
a diagnosis TIO is suspected it is also often difﬁcult to ﬁnd
the responsible FGF23-secreting tumor, since these tumors
are often small, slow growing, benign tumors of mesench-
ymal origin, which can occur almost anywhere in bone or
soft tissue [1–4]. Since the source of the FGF23 production
is often very hard to ﬁnd careful follow-up is necessary.
Regular restaging should be performed until the culprit
lesion is detected [3, 5]. In this article we do not only dis-
cuss the intense long diagnostic workup and follow-up of a
patient with TIO but we also show that when patients are
carefully monitored this can be performed without com-
plications, e.g., tertiary hyperparathyroidism due to phos-
phate suppletion or new fractures.
Case description
A 59-year-old woman with a longstanding history of epi-
lepsy with complex partial seizures, for which she had been
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using phenytoin for more than 20 years, was referred to our
center with a 3-year history of progressive muscle weak-
ness, associated with generalized bone and muscle pain,
resulting in signiﬁcant limitations in her daily activities. The
referring physician’s working diagnosis was osteoporosis
secondary to long-term use of anti-convulsant therapy in the
form of phenytoin. The diagnosis of osteoporosis was made
on the basis of low bone mineral density measurements
using dual-energy X-ray absorptiometry (lumbar T-score
−2.2 standard deviations (SD), femoral neck T-score −3.0
SD) and stress fractures of heels and ankles. The patient was
also found to have a vitamin D deﬁciency, low serum cal-
cium and phosphate concentration (respectively 2.13 and
0.45 mmol/L) and elevated alkaline phosphatase (366 U/L).
Treatment with phenytoin was discontinued. Supplementa-
tion of vitamin D in the form of colecalciferol (vitamin D3)
and calcium carbonate was used in a dosage of 400 IE and
subsequently 500 mg 3 times per day. Subsequently intra-
venous treatment with bisphosphonates (pamidronate) was
initiated before referral to our center. In view of persistence
of complaints, a 99mTc-skeletal scintigraphy was performed,
showing multifocal areas of increased radioactive isotope
uptake, including at the femoral neck bilaterally, interpreted
to be due to multiple insufﬁciency fractures (Fig. 1a). The
patient was referred to our center for further investigation
and management because persistence of symptoms and
hypophosphatemia and inadequate response of bone
mineral density to bisphosphonate after an year of therapy.
At presentation in our center, the patients symptoms had
further worsened with progressive proximal muscle pain
and weakness and increasing bone pain. She was still using
calcium/vitamin D supplementation. Laboratory investiga-
tion conﬁrmed the presence of severe hypophosphatemia. In
retrospect this was also the case at ﬁrst presentation else-
where. She had a normal renal and liver function, the serum
calcium was still low in the presence of a normal para-
thormone, normal 25-hydroxyvitamin D and a low normal
1,25-dihydroxy vitamin D (Table 1). Bone turnover was
elevated as suggested by high alkaline phosphatase. Con-
ventional radiographs demonstrated Looser’s zones in the
femoral neck bilaterally. A diagnosis of hypophosphatemic
osteomalacia was suspected. The 24-h urinary phosphate
was 15 mmol/24 h. The fractional tubular reabsorption of
phosphate (TRP) was low 0.77, calculated by the formula
TRP = 1 − {(Urine phosphate × Serum creatinine)/(Serum
phosphate × Urine creatinine)}. Second morning-void urine
and blood samples are needed taken at the same time
without phosphate supplementation. When TRP is ≤0.86
then the tubular maximum for phosphate corrected for
glomerular ﬁltration rate (TmP/GFR) can be calculated by
the formula TmP/GFR= TRP × serum phosphate, which





Fig. 1 a. Skeletal scintigraphy performed 4 h after injection of 99mTc-
hydroxydiphosphonate showing multiple focal areas of increased
osteoblastic activity suggestive for microfractures together with general
increased osteoblastic activity throughout the whole skeleton,
suggestive for a metabolic bone disease. b.111Indium-pentetreotide
planar total body scintigraphy (24 h after injection) showing
pathological somatostatin receptor expression in the left inguinal
region. c. Fusion transversal image of the 18ﬂuorodeoxyglucose
positron emission tomography/computed tomography (FDG‐PET/CT)
showing a soft tissue lesion with moderately increased glucose
metabolism (maximum standardized uptake value (SUVmax) 4.2 g/cm3
47 min post-injection of 175MBq FDG) in the left inguinal region,
situated in the m. quadrates femoris. On the full-body images, no other
FDG-avid lesions were detected. d. Transversal short tau inversion
recovery (STIR) magnetic resonance image with an intermuscular
located soft tissue mass inferior to the left hip joint. The lesion
demonstrates inhomogeneous high signal intensity compared to
muscle. e. Macroscopy shows a well circumscribed nodular soft
tissue tumor (diameter 6 cm). (black bar= 1 cm). f. Microscopy shows
a tumor composed of bland, spindle to stellate cells, surrounding a
matrix of phosphaturic mesenchymal tumor that typically calciﬁes in a
type of ‘grungy’ or ﬂocculent fashion
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mmol/L). TmP/GFR can also be determined using a
nomogram [6]. The results were compatible with renal
phosphate wasting. Considering the patient’s age, normal
phenotype and negative family history for bone and mineral
disorders, a diagnosis of tumor-induced osteomalacia was
considered. The C-terminal FGF-23 (Immutopics, San
Clemente, CA, USA) was measured in ethylene-diamine-
tetraacetic acid (EDTA) plasma. The BioTek ELx50 (Bio-
Tek, Bad Friedrichshall, Germany) was used as an auto-
matic washing machine. All analyses were performed
according to manufacturer’s protocol [7]. Serum C-terminal
FGF23 was found to be above the upper limit of the normal
laboratory reference of 123 RU/mL (normal value <120
RU/ml), inappropriately high in the presence of hypopho-
sphatemia. An extensive search using different imaging
tools including 111Indium-pentetreotide whole body single
photon emission tomography (SPECT), computed tomo-
graphy (CT) and magnetic resonance imaging (MRI),
revealed no potential lesion as a source of FGF23 produc-
tion. The patient was treated with active vitamin D meta-
bolite (alfacalcidol 1dd1.5 µg) and phosphate drink (3dd20
mmol), which partially increased serum phosphate level
associated with improvement of symptoms. However, this
was insufﬁcient to control hypophosphatemia and asso-
ciated symptoms in the long-term. There was a clear
increase in C-terminal FGF23 (2050 RU/ml) over the fol-
lowing 4 years and it became progressively more difﬁcult to
control serum phosphate levels. Her clinical picture also
signiﬁcant worsened. She had difﬁculty in walking and
surgical intervention was required to stabilize the severe
insufﬁciency fractures of her hips. At that stage further
radiological evaluation using 111Indium-pentetreotide scin-
tigraphy and also a 18Fluorodeoxyglucose positron emission
tomography/CT (FDG-PET/CT) was performed, both
demonstrated a suspicious isolated lesion in the soft tissue
at the left inguinal region (Fig. 1b, c). A MRI conﬁrmed the
presence of a small tumor in the left quadriceps femoris
muscle (Fig. 1d), which was subsequently successfully
resected. The resected lesion was a soft tissue tumor, with
macroscopic features of a nodular tumor with a maximum
diameter of 6 cm (Fig. 1e). Figure 1f shows the histology of
the tumor composed of bland, spindle to stellate cells,
surrounding a matrix of phosphaturic mesenchymal tumor
that typically calciﬁes in a ‘grungy’ or ﬂocculent fashion.
Within 5 days after complete resection of the tumor, there
was a rapid and complete normalization of serum phosphate
and FGF23 levels associated with complete resolution of
the clinical picture.
Discussion
Tumor-induced osteomalacia was ﬁrst described by
McCance in 1947 [8]. In 1959 Prader et al. were the ﬁrst to
recognize that the disease was the result of a tumor which
secreted a ‘rachitogenic’ substance and that resection of the
tumor resulted in resolution of the osteomalacia [9]. A
growing recognition of the disease paralleled the identiﬁ-
cation of FGF23 as a phosphaturic agent in 2000 [10].
Despite unraveling the pathophysiology of TIO, there is still
often delay in establishing the diagnosis because associated
musculoskeletal symptoms are non-speciﬁc, the FGF23-
producing tumor is often very small and its localization very
elusive. A delay in time between onset of symptoms and a
further delay in localization and resection of the FGF23-
producing tumor may be associated with considerable
morbidity because of progressive osteomalacia if the
hypophosphatemia remains untreated or is more difﬁcult to
control if treated with active vitamin D metabolites as the
tumor growth increases production of FGF23, resulting in
increasing renal phosphate wasting.










(5 days after resection)
Reference
range
phosphate (mmol/L) 0.45 0.56 0.53 0.65 1.18 2.15–2.55
calcium (mmol/L) 213 2.08 2.28 2.49 2.39 0.90–1.50
creatinine (µmol/L) – 57 62 85 65 49–90
alkaline phosphatase (U/L) 366 271 115 148 102 0–98
PTH (pmol/L) 7.0 7.8 4.4 1.6 5.4 1.5–8.0
vitamin D 25(OH) (nmol/L) nr 73 78 92 89 50–250
1,25 (OH) 2 vitamin D (pmol/L) – 58 80 – – 40–140
C-FGF23 (*RU/L)/(**U/L) – *123 **1370 **2050 **54 *0–120
**0–125
nr not retainable
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FGF23 is a hormone produced by osteocytes and
osteoblasts. FGF23 acts primarily at the proximal renal
tubule by inhibiting tubular phosphate reabsorption by
reducing the expression of the sodium phosphate co-
transporters NaPi-IIa and NaPi-IIc through activation of
the receptor complex of ﬁbroblast growth factor receptor 1c
and its co-receptor klotho. FGF23 also inhibits the expres-
sion of the renal 1α-hydroxylase enzyme and decreases
thereby 1,25-dihydroxy vitamin D production [11, 12]. The
pathognomonic features of excess circulating FGF23 are
renal tubular wasting of phosphate and suppressed 1,25-
dihydroxy vitamin D levels which further impair intestinal
absorption of phosphate worsening hypophosphatemia and
resulting in impaired mineralization of bone.
A systematic approach to hypophosphatemia helps in the
early recognition and treatment of TIO. Presenting symp-
toms of TIO are diffuse muscle and bone pain, initial
proximal muscle weakness which becomes generalized and
insufﬁciency fractures. A careful history taking and physical
examination is important followed by laboratory investi-
gations including calcium, phosphate, creatinine, para-
thyroid hormone (PTH) and vitamin D metabolites. All
cases of hypophosphatemia should be further evaluated to
establish whether low circulating levels of phosphate are
due to renal phosphate wasting, decreased intestinal
absorption of phosphate or to redistribution of phosphate
from extracellular ﬂuid into cells or into the bone matrix.
Hypophosphatemia can also be caused by several medica-
tions. The underlying pathophysiological mechanism of
medication-induced hypophosphatemia are as mentioned
before or resulting from more than one mechanism. Our
patient was known with prolonged therapy with antic-
onvulsants in the form of phenytoin. These drugs are
inducers of the cytochrome P450 thereby causing increased
vitamin D degradation. They also decrease calcium
resorption in the gut [13]. In our case it was remarkable that
the hypophosphatemia persisted after stopping phenytoin
and vitamin D suppletion, so further evaluation was
required. To determine if hypophosphatemia is the result of
renal phosphate wasting it is necessary to calculate the
TMP/GFR. Once renal phosphate wasting is determined the
measurement of FGF23 is an important next step if para-
thyroid hormone concentration is in the normal range.
FGF23 can be measured using two different assays, the
intact FGF23 assay and the C-terminal FGF23 assay which
detects intact FGF23 peptide and biologically inactive car-
boxyl terminal (C-terminal) fragments. Acquired hypopho-
sphatemia due to renal phosphate wasting is most likely due
to TIO, in which case excess FGF23 is most often produced
by benign, small phosphaturic mesenchymal tumors [1–5,
14]. Malignant tumors and metastases are rare [5]. A benign
phosphaturic mesenchymal tumor may occasionally pro-
gress to a high-grade osteosarcoma [15]. FGF23 secretion
may also be observed in association with rare bone
diseases such as neuroﬁbromatosis, epidermal nevus syn-
drome and isolated ﬁbrous dysplasia or in the setting of
McCune-Albright [16–18]. Other possible causes of renal
phosphate wasting with elevated FGF23 levels include
inherited hypophosphatemic osteomalacia such as X-linked
hypophosphatemic rickets, autosomal dominant hypopho-
sphatemic rickets and autosomal recessive hypopho-
sphatemic rickets. FGF23-independent causes of
hypophoshataemia are alcohol abuse, drugs or toxins, renal
tubular acidosis, Fanconi’s syndrome or hereditary hypo-
phosphatemic rickets with hypercalciuria.
The ﬁnding of hypophosphatemia in the absence of a
family history for bone and mineral disorders, a normal
phenotype and relatively recent onset of symptoms which
may rapidly progress in an adult with previously docu-
mented normal serum phosphate suggest TIO, which may
be conﬁrmed by measuring FGF23 levels (Fig. 2). The
deﬁnitive diagnosis of TIO is established by identiﬁcation
of the causative tumor and by resolution of the clinical
picture following complete tumor resection. Complete sur-
gical resection of the FGF23 secreting tumor is the only
deﬁnitive therapy, which emphasizes the need for localizing
FGF23-producing tumors. Localization of FGF23-
producing tumors can be challenging and a step-wise
approach, including functional imaging, followed by ana-
tomical imaging, and if necessary selective venous sam-
pling may signiﬁcantly improve success in tumor
localization [4]. Tumors associated with osteomalacia
variably express somatostatin receptors (SSTR1–5),
allowing SSTR-based functional imaging by octreotide
scintigraphy such as 111In-pentetreotide [19]. Because pre-
dominant overexpression of SSTR-2 subtype in tumors of
TIO, 68Ga-octreotide PET/CT may have an important role
in localization of the culprit lesion, and may potentially
reduce signiﬁcant delay in establishing the diagnosis of TIO
[20]. FDG-PET/CT can conﬁrm a lesion or identify a lesion
that was not initially seen on octreotide scintigraphy [4, 20].
FDG-PET/CT has been proven to be sensitive but not a
speciﬁc method of identifying FGF23-producing tumors.
PET/CT using 68-gallium is expected to be much more
speciﬁc and informative for this kind of tumors but is often
not available in many centers [5]. Anatomic imaging is used
to conﬁrm the localization of a tumor. When multiple sus-
picious lesions are identiﬁed selective venous sampling can
increase diagnostic power by conﬁrming the localization of
the culprit lesion [21]. Furthermore establishing the diag-
nosis of an FGF23-producing phosphaturic mesenchymal
tumor requires an adequate integration of the clinical picture
in correlation with radiology and histology in a multi-
disciplinary setting, since radiology and histology show
considerable overlap with other entities that need different
treatment and harbor other clinical outcomes.
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Since identifying the source of FGF23 overproduction
may be challenging and often inconclusive in patients with
TIO, medical treatment should be initiated. Phosphate
treatment alone will not be sufﬁcient and can be counter-
productive since oral phosphate stimulates PTH secretion
and is poorly absorbed due to impaired 1,25-dihydroxy
vitamin D hydroxylation. Furthermore, the compliance of
oral phosphate is rather low since this is often not well
tolerated. Therefore treatment with active vitamin D meta-
bolites is necessary since FGF23 not only increases urinary
phosphate loss but inhibits the expression of 1α-hydro-
xylase as well, leading to a decreased 25-hydroxyvitamin D
to 1,25-dihydroxy vitamin D hydroxylation. Intestinal
absorption of dietary phosphate will be impaired since the
expression of type 2b sodium phosphate co-transporter is
downregulated due to the lack of 1,25-dihydroxy vitamin D.
Furthermore the decrease in 1,25-dihydroxy vitamin D sti-
mulates the synthesis and secretion of PTH by the para-
thyroid glands thereby furthermore inducing urinary
phosphate loss. By supplementation of active vitamin D
metabolites you increase the intestinal absorption of phos-
phate and suppress PTH production and should therefore be
the drug of choice. In cases the hypophosphatemia is severe
oral phosphate can be added with close monitoring of the
PTH levels and urinary calcium excretion since this will
increase urinary calcium excretion which can lead to
nephrocalcinosis and nephrolithiasis. Therapy should be
continued for as long as the tumor is not identiﬁed or
resected. Patients should also be closely monitored for
complications of the hypophosphatemia, because long-
standing hypophosphatemia can lead to progression of
osteomalacia and associated increased risk of fractures.
Adenosine triphosphate (ATP) depletion in hypopho-
sphatemia can also effect the cardiopulmonary system by
impaired myocardial and diaphragmatic contractility and
effect the hematopoietic system leading to hemolysis and
leukocyte dysfunction, these complications are rare [22].
The search for the source of FGF23 should also continue
using state of the art imaging techniques.
Surgical intervention is curative when a lesion is iden-
tiﬁed and fully resected. Radical excision is important to
avoid a recurrence. After successful tumor resection, the
serum level of FGF23 decreases to a normal level within a
few hours to days depending on the magnitude of the initial
elevation (half-life of FGF23 is approximately 46–58 min)
[23]. Improvement of clinical symptoms rapidly follows
with subsequent complete remineralization of the skeleton
[19]. Late recurrence due to local recurrence or distant
metastasis is very uncommon and occurs in approximately
less than 5 % of patients with TIO [2, 3]. Long-term follow-
up is recommended, FGF23 can be used as a tumor marker
for early detection of recurrences.
Conclusion
Tumor-induced osteomalacia represent a signiﬁcant diag-
nostic challenge and should be considered in the differential
diagnosis of all patients with musculoskeletal symptoms
associated with hypophosphatemia. Association of hypo-
phosphatemia, renal phosphate wasting (low TRP/low TmP/
GFR), elevated FGF23 levels and paradoxically low or
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normal 1,25-dihydroxy vitamin D suggests the diagnosis of
TIO after exclusion of the hereditary hypophosphatemic
osteomalacia by adult onset of hypophosphatemia in the
absence of family history and characteristic phenotype.
Awareness of this acquired metabolic abnormality, a sys-
tematic approach and evaluation of a hypophosphatemia in
a multidisciplinary setting are of pivotal importance because
early recognition and treatment can prevent progression of
osteomalacia and associated increased risk of fractures.
Patients should be prescribed active metabolites of vitamin
D with a few requiring additional phosphate supplementa-
tion. After the FGF23-producing tumor is located and fully
resected, long-term follow-up is advocated for early diag-
nosis of a potential recurrence.
Compliance with ethical standards
Conﬂict of interest The authors declare that they have no conﬂict of
interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. N. Weidner, D.S. Cruz, Phosphaturic mesenchymal tumors a
polymorphous group causing osteomalacie or rickets. Cancer 59,
1442–1454 (1987)
2. A.L. Folpe, J.C. Fanburg-Smith, S.D. Billings, M. Bisceglia,
F. Bertoni, J.Y. Cho et al., Most osteomalacia-associated
mesenchymal tumors are a single histopathologic entity: an ana-
lysis of 32 cases and a comprehensive review of the literature. Am
J Surg Pathol. 28(1), 1–30 (2004)
3. Y. Jiang, W.B. Xia, X.P. Xing, B.C. Silva, M. Li, O. Wang et al.,
Tumor-induced osteomalacia: an important cause of adult-onset
hypophosphatemic osteomalacia in China: Report of 39 cases and
review of the literature. J Bone Miner Res. 27(9), 1967–1975
(2012)
4. W.H. Chong, P. Andreopoulou, C.C. Chen, J. Reynolds, L.
Guthrie, M. Kelly et al., Tumor localization and biochemical
response to cure in tumor-induced osteomalacia. J Bone Miner
Res. 28(6), 1386–1398 (2013)
5. W.H. Chong, A.A. Molinolo, C.C. Chen, M.T. Collins, Tumor-
induced osteomalacia. Endocr Relat Cancer 18(3), R53–R77
(2011)
6. O.L. Bijvoet, Relation of plasma phosphate concentration to renal
tubular reabsorption of phosphate. Clin Sci. 37(1), 23–36 (1969)
7. A.C. Heijboer, M. Levitus, M.G. Vervloet, P. Lips, P.M. ter Wee,
H.M. Dijstelbloem et al., Determination of ﬁbroblast growth
factor 23. Ann Clin Biochem. 46, 338–340 (2009)
8. R.A. McCance, Osteomalacia with Looser’s nodes (Milkman’s
syndrome) due to a raised resistance to vitamin D acquired about
the age of 15 years. Q J Med. 16(1), 33–46 (1947)
9. A. Prader, R. Illig, E. Uehlinger, G. Stalder, Rickets following
bone tumor. Helv Paediatr Acta. 14, 554–565 (1959)
10. ADHR Consortium, Autosomal dominant hypophosphataemic
rickets is associated with mutations in FGF23. Nat Genet. 26(3),
345–348 (2000)
11. F. Perwad, M.Y. Zhang, H.S. Tenenhouse, A.A. Portale, Fibro-
blast growth factor 23 impairs phosphorus and vitamin D meta-
bolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-
hydroxylase expression in vitro. Am J Physiol Renal Physiol. 293
(5), F1577–F1583 (2007)
12. X. Yan, H. Yokote, X. Jing, L. Yao, T. Sawada, Y. Zhang et al.,
Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi
co-transporter by signaling through a receptor functionally distinct
from the known FGFRs in opossum kidney cells. Genes Cells. 10
(5), 489–502 (2005)
13. G. Liamis, H.J. Milionis, M. Elisaf, Medication-induced hypo-
phosphatemia: a review. QJM. 103(7), 449–459 (2010)
14. N. Weidner, Review and update: oncogenic osteomalacia-rickets.
Ultrastruct Pathol. 15(4-5), 317–333 (1991)
15. A. Ogose, T. Hotta, I. Emura, H. Hatano, Y. Inoue, H. Umezu
et al., Recurrent malignant variant of phosphaturic mesenchymal
tumor with oncogenic osteomalacia. Skeletal Radiol. 30(2),
99–103 (2001)
16. R. Ivker, S.D. Resnick, R.A. Skidmore, Hypophosphatemic vita-
min D-resistant rickets, precocious puberty, and the epidermal
nevus syndrome. Arch Dermatol. 133(12), 1557–1561 (1997)
17. K. Konishi, M. Nakamura, H. Yamakawa, H. Suzuki, T. Saruta,
H. Hanaoka et al., Hypophosphatemic osteomalacia in von
Recklinghausen neuroﬁbromatosis. Am J Med Sci. 301(5),
322–328 (1991)
18. M. Riminucci, M.T. Collins, N.S. Fedarko, N. Cherman, A. Corsi,
K.E. White et al., FGF-23 in ﬁbrous dysplasia of bone and its
relationship to renal phosphate wasting. J Clin Invest. 112(5),
683–692 (2003)
19. S.M. Jan de Beur, E.A. Streeten, A.C. Civelek, E.F. McCarthy,
L. Uribe, S.J. Marx et al., Localisation of mesenchymal tumours
by somatostatin receptor imaging. Lancet. 359(9308), 761–763
(2002)
20. R.J. Clifton-Bligh, M.S. Hofman, E. Duncan, I. Sim, D. Darnell,
A. Clarkson et al., Improving diagnosis of tumor-induced osteo-
malacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol
Metab. 98(2), 687–694 (2013)
21. P. Andreopoulou, C.E. Dumitrescu, M.H. Kelly, B.A. Brillante, C.
M. Cutler Peck, F.M. Wodajo et al., Selective venous catheter-
ization for the localization of phosphaturic mesenchymal tumors. J
Bone Miner Res. 26(6), 1295–1302 (2011)
22. J. Amanzadeh, R.F. Reilly, Hypophosphatemia: an evidence-
based approach to its clinical consequences and management. Nat
Clin Pract Nephrol. 2(3), 136–148 (2006)
23. A. Khosravi, C.M. Cutler, M.H. Kelly, R. Chang, R.E. Royal, R.
M. Sherry et al., Determination of the elimination half-life of
ﬁbroblast growth factor-23. J Clin Endocrinol Metab. 92(6),
2374–2377 (2007)
Endocrine (2016) 54:642–647 647
